UCL Cancer Institute

Selected Publications

Khan MS, Tsigani T, Rashid M, Rabouhans JS, Yu D, Luong TV, Caplin ME, Meyer T. Circulating Tumour Cells and EpCAM Expression in Neuroendocrine Tumours. Clin Canc Res 2011 Jan 15;17(2):337-45  (Pubmed)

Meyer, T.,Caplin,M.E., Palmer, D.H., Valle, J.W., Larvin,M., Waters,J.S., Coxon, F., Borbath, I., Peeters.M., Nagano,E., Kato,H. A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. European Journal of Cancer 2010, 46; 526–533  (Pubmed)

Forster MD, Saijo N, Seymour L, Calvert H. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan Clin Cancer Res. 2010 Mar 15;16(6):1737-44  (Pubmed)

Meyer T, Gaya A, Dancey G, Stratford M, Othman S, Sharma S, Wellsted D, Taylor J, Stirling J, Poupard L, Folkes L, Chan P, Pedley RB, Chester KA, Owen K, John A Violet, Malaroda A, Green AJ, Buscombe J, Padhani AR, Rustin GJ, Begent RH. A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas. Clinical Cancer Research 2009 15(13):4484-92  (Pubmed)

D. Hochhauser, T. Meyer, P. Loadman, V. J. Spanswick, M. Cobb, R. H. Begent, J. Wu, P. H. Clingen, J. A. Hartley, D. Jodrell. Phase I study of the DNA minor groove binding pyrrolobenzodiazepine dimer (SJG 136) administered every 21 days in patients with advanced solid tumours. Clinical Cancer Research (2009) 15;15(6):2140-7  (Pubmed)